Darzalex sales exceed expectations in second quarter
Sales of Johnson & Johnson's drug Darzalex totaled USD 1.43bn in Q2, far surpassing analysts' expectations for the drug, which was originally developed by Genmab.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
At the half-way point of 2021, Genmab-developed drug Darzalex is close to achieving triple-blockbuster status, after a significant growth in sales compared to last year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen gets FDA approval for new Darzalex combination
For subscribers
Genmab surpasses 1,000 employees
For subscribers
.jpg)
.jpg&w=384&q=75)
